Which device is used for self-administered treatment in mild nerve agent exposure?

• A. Naloxone auto-injector
• B. ATANA auto-injector
• C. EpiPen
• D. Inhaler

Answer: (B)

In mild nerve agent exposure, rapid countermeasure is a combined antidote auto-injector that delivers atropine and pralidoxime in one device, designed for self-use in the field. Atropine blocks the dangerous muscarinic effects of nerve agents (like excessive secretions, bronchorrhea, bronchospasm, and bradycardia), while pralidoxime helps regenerate acetylcholinesterase, reducing both muscarinic and nicotinic symptoms when given early. The ATANA auto-injector is specifically built for this purpose, so a casualty can administer life-saving treatment quickly without waiting for medical personnel.

The other tools address different emergencies. A naloxone auto-injector treats opioid overdose; an EpiPen is for severe allergic reactions; an inhaler is for conditions like asthma or COPD. None of these tackle the cholinergic crisis caused by nerve agents, which is why the nerve agent antidote auto-injector is the best choice for self-treatment in this scenario.